Michael Makris/LinkedIn
Feb 25, 2026, 16:34
Michael Makris: Biomarin Has Decided to Withdraw Roctavian from the Market
Michael Makris, Emeritus Professor of Haemostasis and Thrombosis at the University of Sheffield, shared on LinkedIn:
”IMPORTANT.
Biomarin has decided to withdraw Roctavian, the only approved Haemophilia A gene therapy, from the market.
Biomarin announced several months ago that it wanted to sell Roctavian to another company, but since they failed to find a buyer, they made the decision to voluntarily withdraw Roctavian from the market.
The problem was not that this did not work, but rather that there are a lot of other highly effective choices for haemophilia A subjects available.”
Stay updated with Hemostasis Today.
-
Feb 25, 2026, 16:25Tagreed Alkaltham: The Blood Banker Personality
-
Feb 25, 2026, 16:17Sanjay Ahuja: Insightful Talk on 100 Years of VWD by Jorge Di Paola
-
Feb 25, 2026, 15:20Michael Shapiro։ Creating Real Pathways for Trainees in Preventive Cardiology
-
Feb 25, 2026, 15:15Ajay Kumar: Plasma Component Quality Control Standards
-
Feb 25, 2026, 15:09Wolfgang Miesbach: Efficacy, Safety and Thrombosis Signals in Haemophilia A/B with Inhibitors
-
Feb 25, 2026, 15:06Nasrin Haghani: How Vitamin K2 Reduces Arterial Plaque Buildup and Promotes Heart Health
-
Feb 25, 2026, 14:33Ahmad Hazri Mohamed Aris: Drafting the 2026–2030 Indonesia PACT National Access Plan with IHS
-
Feb 25, 2026, 14:28Abdul Mannan: Preventing Transfusion Death Starts with Early Recognition of TACO
-
Feb 25, 2026, 14:23Obi Light Ogbonnia: The Power of Lived Experience in Health Policy and Research